Navigation Links
Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom
Date:7/25/2011

BARCELONA, Spain and GERRARDS CROSS, England, July 26, 2011 /PRNewswire/ --


Veeva Systems announced today that Daiichi Sankyo, one of the world's top 20 pharmaceutical companies, is replacing its legacy, on-premise Customer Relationship Management (CRM) system with Veeva CRM in the UK. Daiichi Sankyo will deploy Veeva CRM to all of its commercial teams in the UK including integrated healthcare, specialty care, medical liaison scientists, and head-office teams (i.e., marketing and medical) to drive more effective customer engagement.

Daiichi Sankyo had outgrown its current CRM system, according to executives. "Most of our customer-facing teams were only using the system as a basic customer information repository," said Dr. Simon Clough, managing director for Daiichi Sankyo UK. "It lacked important functionality and so became nothing more than an expensive database to record calls. We were looking for a system that offered functionality well beyond just call recording."

After researching alternative CRM systems, Daiichi Sankyo decided on Veeva CRM. "We're all about innovation that leads to enhanced quality and value for our customers," said Clough. "We've adopted an innovative agenda for advancing everything from our science to our interactions with stakeholders, and Veeva CRM supports it perfectly. The system's intuitive, easy-to-use interface and rich functionality are part of our strategy for strengthening customer engagements in the UK's changing NHS environment."

Daiichi Sankyo was also drawn to Veeva iRep, which is the first integrated Pharma CRM and CLM solution designed for the Apple iPad. Clough continued, "We recognised that the system's closed-loop marketing functions and the device's beautiful presentation of multi-media content would support more interactive customer engagements. With iRep, we expect that our account specialists will be more connected, responsive, and effective."  '/>"/>

SOURCE Veeva Systems and Daiichi Sankyo
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. DAIICHI SANKYO EUROPE GmbH Selects DATATRAK eClinical™ for Pan-European Systolic Hypertension Study
2. Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs
3. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
4. EdgeBio Selects Calipers Sample Preparation Suite for High Throughput and Benchtop Sequencing Workflows
5. St. Lukes Hospital & Health Network Selects CareTech Solutions to Provide Proactive Monitoring of Hospital IT Infrastructure
6. Pantec Biosolutions Selects Oclaro Laser Diode Bars for Transdermal Drug Delivery and Tissue Ablation Systems
7. TGAC Selects Caliper Solutions for High Throughput Sequencing Pipeline
8. Lifeline Skin Care™ Selects Click Here, Inc., Richards Partners
9. Catalysis Foundation for Health Selects BioFortis Labmatrix Database Software for International Tuberculosis Diagnostic Biomarker Study
10. Top 5 Global Pharmaceutical Company Selects NewCardios QTinno for 2 Upcoming Phase I Drug Safety Trials
11. West Coast Clinical Trials Selects OmniComm Systems TrialOne® Suite to Automate Phase I Clinic Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... CORAL SPRINGS, Florida , September 19, 2014 /PRNewswire/ ... biotech companies release latest developments, patents and results of ... (OTC: GNSZ), Eli Lilly and Company (NYSE: ... ), Celgene Corporation (NASDAQ: CELG ) and ... (OTCQB: GNSZ), a leader in developing prodrug therapeutics for ...
(Date:9/19/2014)... , September 19, 2014 ... 53rd European Society for Paediatric Endocrinology (ESPE) Meeting  ... science and medical research in the field of growth  ... KGaA, Darmstadt, Germany , today announced ... (GGI) for 2014. The awards were announced during a ...
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... near-patient testing, is performed outside a clinical laboratory. ... hence in administrating appropriate treatments and medication. POCT ... and prevalence of lifestyle diseases such as diabetes, ... and user-friendly. POCT devices are standardized to minimize ...
(Date:9/18/2014)... 18, 2014 ... ) has announced the addition of ... Strategic Business Report" report to ... report analyzes the worldwide markets for ... the following Product Segments: Polymeric Materials, ...
Breaking Biology Technology:Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3
... BIRMINGHAM, Ala., Sept. 19 BioCryst,Pharmaceuticals, Inc. ... findings,from a Phase II study with intramuscular ... for the treatment of seasonal and,life-threatening influenza. ... The study was a randomized, double-blind, placebo-controlled ...
... ,Arpida Ltd (SWX: ARPN) presented a large body ... iclaprim at the 47th annual Interscience,Conference on Antimicrobial ... major scientific conference where thousands of scientists and,clinicians ... the latest,developments in the field of infectious diseases. ...
... bacterial contamination in ... platelets, WORCESTER, ... for detecting bacterial contaminants in,blood cells and tissue, has received 510 (k) ... Administration (FDA). This provides,Verax authorization to market the device, which cuts the ...
Cached Biology Technology:BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 2BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 3BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 4BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 5BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 6BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 7Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC 2Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC 3Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC 4Verax Biomedical Receives 510 (k) Clearance from FDA for Platelet PGD Test 2Verax Biomedical Receives 510 (k) Clearance from FDA for Platelet PGD Test 3
(Date:9/18/2014)... International Space Station ever starts a "frequent flyers" program, ... Recently the orbiting laboratory has hosted increasing numbers of ... from the space station in April, and another is ... experiment is planned to launch in December. , Fruit ... the world-- and in space. Model organisms can reveal ...
(Date:9/18/2014)... DNA, tiny strands of nucleic acid that contain instructions ... genetic data, our DNA is copied into RNA molecules, ... tasks in our cells. , Several years ago, ... all other known RNAs, this molecule is circular, and ... little has been known about how they are produced. ...
(Date:9/18/2014)... Dogs generally seem to be cheerful, happy-go-lucky characters, so ... outlook on life. , In fact some dogs ... University of Sydney shows. , "This research is ... in dogs objectively and non-invasively. It offers researchers and ... and how that changes," said Dr Melissa Starling, from ...
Breaking Biology News(10 mins):Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2Dogs can be pessimists too 2Dogs can be pessimists too 3
... worldwide battle to curtail malaria, one of the most prevalent ... drug has fallen by the wayside as the malaria parasite ... sweet wormwood plant, Artemisia annua , remains as an ... combined with other antimalarial medications to make it less prone ...
... Valley, NY. (Dec. 20, 2012) When different types ... them aid in repairing central nervous system (CNS) trauma, ... A Belgian research team carried out research aimed at ... cells - neural stem cells, mouse embryonic fibroblasts, dendritic ...
... have developed a statistical explanation for why some things are ... "We,ve built the first mathematical model that uses a bird,s ... Emory biologist Samuel Sober. "We hope it will help us ... Sober conducted the research with physiologist Michael Brainard of ...
Cached Biology News:New whole plant therapy shows promise as an effective and economical treatment for malaria 2New whole plant therapy shows promise as an effective and economical treatment for malaria 3New whole plant therapy shows promise as an effective and economical treatment for malaria 4Cell Transplantation study investigates fate and function of cells transplanted to the CNS 2Doing the math for how songbirds learn to sing 2
Human sIL-2R/CD25 ELI-PAIR Kit...
Rabbit polyclonal to Factor IX ( Abpromise for all tested applications). entrezGeneID: 2158 SwissProtID: P00740...
Rabbit polyclonal to Phosphothreonine-Proline / Phosphoserine-Proline ( Abpromise for all tested applications)....
Mouse monoclonal [7C6] to Bcr-abl ( Abpromise for all tested applications). SwissProtID: P11274...
Biology Products: